Monday, October 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 11, 2026

Notable analyst calls this week: Netflix, Carvana and Marvell Technology among top picks

View original at seekingalpha.com
Notable analyst calls this week: Netflix, Carvana and Marvell Technology among top picks [Wall Street in New York City] JaysonPhotography/iStock via Getty Images The S&P 500 (SP500 [https://seekingalpha.com/symbol/SP500#hasComeFromMpArticle=false#source=section%3Amain_content%7Cbutton%3Abody_link%7Cfirst_level_url%3Ane…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Dell could see some upside in the near term for AI servers with a potential demand/sentiment shift in the market as Dell uses its 10x AI server teams versus peers, fortress balance sheet, and estimated $85B five-quarter pipeline

    60% confidence
  • BofA increased its 2026-28 projections to reflect stronger product margins and elevated energy prices, with 2026 earnings before interest, taxes, depreciation and amortization expected to climb meaningfully

    60% confidence
  • Netflix should achieve double-digit revenue growth over the next three to four years thanks to its advertising business—expected to grow to ~$9.5B by 2030—and increased subscription prices

    60% confidence
  • Netflix can now focus on its strategic roadmap of capital allocation towards content, including more live events, and returning capital to shareholders, with the distraction of battling Paramount Skydance for control of Warner Bros. behind it

    60% confidence
  • Marvell is first and foremost an optical company, and with ports growing rapidly, the market growth carries the name alone. Industry checks suggest optical ports should double in 2026 and double again in 2027

    60% confidence
  • Higher average selling prices, or ASPs, for PCs could offset some near-term unit headwinds as they see Dell taking PC share in 2026

    60% confidence
  • UBS expects revenue beats for ServiceNow for the next few quarters to be less than normal and current remaining performance obligations to decline slightly

    60% confidence
  • Carvana is positioned for high levels of sustained growth long term but think the medium term could see some level of increasing industry competition, with consumer demand resilient but gross profit per unit seeing some headwinds

    60% confidence
  • ServiceNow is better positioned for this AI era relative to other application software firms, and hence it has been our only Buy-rated application software stock, as we've been quite cautious on the broader group. Given that our confidence in that view has weakened and we're hearing more anecdotes of non-AI apps software budget pressure, we're moving to a Neutral rating despite the material YTD de-rating in the stock to 15x 2026 FCF

    60% confidence
  • Pricing strength tied to supply disruptions could fade as markets normalize

    60% confidence
  • Much of the recent upside for LyondellBasell driven by geopolitical disruptions is already reflected in the stock. Shares have rallied on Iran conflict tailwinds which we expect to be fleeting

    60% confidence

Data points we hold from this source

Dell Technologies · pipeline value85 USD
Dell Technologies · stock price target215 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com
Notable analyst calls this week: Netflix, Carvana and Marvell Technology among top picks — Source | Via News | ViaNews Market